Ask three people in a pharma organization what "competitive intelligence" means and you'll likely get three different answers. To someone in R&D, it's pipeline tracking and clinical trial design. To someone in market access, it's pricing and formulary positioning. To someone on the brand or digital marketing team, it usually comes down to one question: what is our competitor actually doing right now, and how does it compare to what we're doing?
That last version of the question is where most competitive intelligence quietly falls short, because the answer usually comes from a modeled spend estimate rather than anything the brand team can actually see. A third-party tool estimates that a competitor spent roughly a certain amount on TV or digital last quarter, based on aggregated market data, and that number gets treated as the competitive picture. It isn't one. A spend estimate can suggest scale. It can't show you what the competitor's ad said, where it ran, or whether the audience it was aimed at ever saw it.
A McKinsey analysis of new drug launches found that roughly two-thirds failed to meet their prelaunch sales forecasts in the first year on the market, and that underperformance tends to persist for years after (McKinsey, based on launches between 2003 and 2009, still the most cited benchmark on this question). Incomplete competitive intelligence isn't the only reason launches miss their number, but a brand that's planning against a modeled guess of what competitors are doing is planning with a real blind spot built in.
"Competitive intelligence" in pharma isn't one discipline. It's several, and teams often bundle them together without realizing they require completely different data and methods.
Pipeline and clinical intelligence tracks competitor trial design, endpoints, enrollment progress, and regulatory filings, mostly relevant to R&D, medical affairs, and portfolio strategy teams making go/no-go and differentiation decisions years before launch.
Market and perception intelligence tracks how HCPs and patients actually think and feel about competing brands: awareness, trial, usage, and switching intent, usually gathered through primary research like surveys and panels.
Commercial and media intelligence tracks what competitors are actively doing in market right now: promotional spend, creative, channel mix, and how that activity is landing with the target audience. This is the category that spend-estimate tools were built to approximate, and it's the one this post focuses on.
Regulatory and access intelligence tracks pricing, reimbursement decisions, and policy shifts that affect how a competing product gets to patients.
ZoomRx covers all four categories, but through different tools. Pipeline and conference intelligence runs through Ferma, brand perception tracking runs through ATU studies, and commercial and media intelligence, the focus of this post, runs through Media Tracking, including Digital Tracker for digital and AI-platform activity specifically. If you landed here looking for pipeline or regulatory intelligence, the market and competitive intelligence solutions is a better starting point than this post.
For commercial and media intelligence specifically, the default methodology for years has been modeled spend estimation. A vendor aggregates market-level data (think media buying patterns, ad network data, or survey-based recall) and produces an estimate of what a competitor likely spent on a given channel over a given period.
That approach made sense when the alternative was nothing. It also has a structural ceiling. A modeled estimate can tell a brand team the rough order of magnitude a competitor is spending. It generally can't tell them what the competitor's ad actually said, which specific sites or platforms it ran on, whether the audience it targeted is the same one the brand cares about, or whether that competitor just changed its message ahead of a launch. Those questions require observing the creative itself, not modeling the spend behind it.
Creative-level visibility means capturing the actual asset a competitor is running, not an estimate of what it cost to run it. In practice, that looks like:
Digital Tracker builds this by passively observing verified HCP and patient panelists across six digital channels plus TV and AI platforms like Google AI Overviews and Med AI tools, all from a confirmed target audience rather than a modeled sample. That's a different kind of evidence than a spend model produces: it's what the audience actually saw, not what a competitor is estimated to have paid for.
Not every stage of a product's lifecycle needs the same type of competitive intelligence, and treating them the same is part of why some programs end up expensive and unfocused.
Early in development, pipeline intelligence and early perception data matter more than commercial activity, since there's often no promotional footprint to track yet. As a brand approaches launch, commercial and media intelligence becomes more useful: understanding which channels competitors are already using to shape the conversation, and which sources are already influencing how the target audience researches the category, including AI-generated answers.
After launch, the priority usually shifts to a recurring cadence: tracking share of voice against named competitors, watching for messaging or channel shifts that signal a competitive response, and connecting that activity back to brand health metrics so a media plan can be adjusted based on evidence instead of a quarterly spend estimate that's already out of date by the time it arrives.
Competitive intelligence in pharma is broader than any one vendor or dataset can cover, and it's worth being clear about which category a brand actually needs before buying into a tool built for a different one. For the commercial and media slice of that picture specifically, the shift worth paying attention to is the move away from modeled spend estimates and toward direct, verified observation of what competitors are actually running, where, and to whom.
If that shift is one your team is already navigating, the Digital Tracker team can walk you through what verified observation looks like for your therapeutic area.